Aurobindo Pharma stock | 2026 earnings growth & current analysis

Aurobindo Pharma

NSEI:AUROPHARMA

Rp 1.307,80

Rp0,00 (0,00%)

1.307,80 Rp

Rp0,00 (0,00%)

End-of-day quote: 03/27/2026

Aurobindo Pharma Stock Value

Analysts currently rate NSEI:AUROPHARMA as Outperform.

Outperform

Aurobindo Pharma Company Info

EPS Growth 5Y

4,51%

Market Cap

Rp759,57 B

Long-Term Debt

Rp15,62 B

Annual earnings

05/26/2026 (E)

Dividend

Rp7,98

Dividend Yield

0,61%

Founded

1986

Industry

Health Care

Country

India

Website

Aurobindo Pharma

ISIN Number

INE406A01037

Website

http://www.aurobindo.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp1.385,00

5.9%

Last Update: 03/28/2026

Analysts: 26

Highest Price Target Rp1.640,00

Average Price Target Rp1.385,00

Lowest Price Target Rp1.020,00

In the last five quarters, Aurobindo Pharma’s Price Target has fallen from Rp1.460,81 to Rp1.291,50 - a -11,59% decrease. Twenty Five analysts predict that Aurobindo Pharma’s share price will increase in the coming year, reaching Rp1.385,00. This would represent an increase of 5,90%.

Top growth stocks in the health care sector (5Y.)

What does Aurobindo Pharma do?

Aurobindo Pharma Limited engages in the manufacture of generic formulations and active pharmaceutical ingredients. Business Segments The company divides its operations into several key segments that underscore its extensive capability in pharmaceutical development and manufacturing. The main segments include: Generic Pharmaceuticals: The company specializes in the development and manufacturing of generic formulations across various therapeutic areas. This segment serves as the primary revenu...

Aurobindo Pharma Limited engages in the manufacture of generic formulations and active pharmaceutical ingredients.

Business Segments

The company divides its operations into several key segments that underscore its extensive capability in pharmaceutical development and manufacturing.

The main segments include:

Generic Pharmaceuticals: The company specializes in the development and manufacturing of generic formulations across various therapeutic areas. This segment serves as the primary revenue driver, showcasing a vast array of products that are both affordable and accessible. The company’s robust research pipeline is continually evolving, with concerted efforts directed towards launching new generic drugs to address unmet medical needs.

Active Pharmaceutical Ingredients (APIs): The company is recognized as one of the largest manufacturers of APIs, which are key components in pharmaceutical formulations. This segment not only supplies materials to its in-house formulations but also caters to external customers worldwide, enhancing the overall operational efficiency of the company.

Research and Development: The company R&D division focuses on creating innovative formulations and improving existing products through scientific research and technological advancements. The commitment to R&D ensures that Aurobindo Pharma stays ahead in the competitive pharmaceutical landscape, working on complex generics and biosimilars.

International Business: The company international footprint is global, with a significant presence in more than 150 countries, including the United States, Europe, and various emerging markets. The company leverages its wide-reaching operational footprint to maximize its market share and focus on regulatory compliance in various jurisdictions.

Injectables and Biosimilars: The company has invested in the injectables segment and the development of biosimilars. This strategy underscores its objective to utilize advanced technology to enhance the delivery and effectiveness of its products while catering to specialized patient populations.

Business Strategy

The company business strategy revolves around sustainable growth, innovation, and market leadership. The company to achieve this through the diversification of its product portfolio, investment in technological advancement, and strategic expansions into new markets and therapeutic areas.

The company invests heavily in research and development, focusing on launching first-to-market products and complex generics, which require substantial scientific expertise. This dedicated approach helps the company tap into lucrative segments with high barriers to entry where generic alternatives are in demand.

Products and Services

The company offers a diverse array of pharmaceutical products and services that cater to a wide range of health conditions. The company's product portfolio can be categorized as follows:

Generic Formulations: The company provides an extensive line of generic medications across multiple therapeutic areas, including anti-infectives, cardiovascular treatments, pain management, CNS disorders, and gastroenterology, among others.

Active Pharmaceutical Ingredients (APIs): The company manufactures a comprehensive range of APIs that serve both internal and external markets. This segment supports the company’s overarching goals of vertical integration and cost efficiency.

Injectables: The company has developed a line of injectable products, focusing on both sterile injectables and complex formulations. This expansion into injectables highlights to address specialized patient needs and enhance therapeutic options.

Research and Development Services: The company invests in R&D to innovate and improve existing products, providing customized solutions to partners and contributing to the overall development of the pharmaceutical sector.

Biosimilars: The company has entered the growing market segment of biosimilars, developing alternative biologics that offer similar efficacy to established therapeutic biologics at a reduced cost.

Geographical Markets

The company operates in a diverse set of geographical markets, catering to both regulated and emerging economies. The company's primary markets include the United States, European Union countries, and various emerging markets in Asia, Africa, and Latin America.

Seasonality

The company operates on a continuous basis with a steady demand for its products across various therapeutic areas. The consistent need for essential medications and generics across diverse markets contributes to a stable revenue stream throughout the year.

Customers

The company serves a diverse clientele, which includes healthcare providers, hospitals, pharmacies, and various government and non-government institutions. The company's customer base spans over 150 countries, with a specific emphasis on meeting the needs of both regulated markets, such as North America and Europe, as well as emerging economies. By providing affordable medications, enhances patient access to healthcare, working diligently to meet the needs of millions.

Trade Names

The company holds a diverse portfolio of trade names, trademarks, and patents associated with its products. The company continuously seeks to protect its intellectual property while innovating new therapeutics. Details regarding the number of patents and their respective expiration dates are maintained in accordance with regulatory guidelines, ensuring compliance and protection of proprietary technologies.

Sales and Marketing

The company employs a multifaceted marketing strategy that includes direct sales, partnerships, and collaborations with distribution channels. It utilizes digital marketing, trade shows, and outreach programs to educate healthcare professionals about its products. The distribution network is designed to ensure timely product delivery across global markets, enhancing the company's responsiveness to customer needs.

Government Regulations

The company operates within a complex regulatory environment governed by stringent local and international laws aimed at ensuring pharmaceutical quality, safety, and efficacy. Compliance with regulations such as the Drug and Cosmetics Act in India and various FDA guidelines in the US is foundational to the company's operational practices. Additionally, Aurobindo Pharma remains committed to environmental sustainability and adheres to environmental laws at minimizing its ecological footprint. The company employs best practices in waste management, emission control, and energy conservation, aligning its operations with governmental environmental policies.

History

Aurobindo Pharma Limited, was founded in 1986. The company was incorporated in 1986.

Aurobindo Pharma Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Products:** 75% **Active Pharmaceutical Ingredients (APIs):** 15% **Antiretroviral Medicines:** 10% **TOP 3 Markets:** **USA:** 45% **Europe:** 25% **India:** 15% Aurobindo Pharma Limited generates the majority of its revenue from pharmaceutical products, followed by...

At which locations are the company’s products manufactured?

**Production sites of Aurobindo Pharma Limited:** Aurobindo Pharma Limited mainly produces its products in India. The company has several production facilities located in different states of India, including Andhra Pradesh and Telangana. These sites specialize in the manufacturing of generic drugs,...

What strategy does Aurobindo Pharma pursue for future growth?

**Focus on Research and Development:** Increase in R&D spending by 10% (2024) **Expansion into New Markets:** Planned market entries in Southeast Asia and Latin America (2025) **Diversification of Product Portfolio:** Introduction of 20 new products in the field of biopharmaceuticals (2025) A...

Which raw materials are imported and from which countries?

**Main raw materials:** Active Pharmaceutical Ingredients (APIs), excipients **Main importing countries:** China, USA, Europe Aurobindo Pharma Limited mainly imports active pharmaceutical ingredients (APIs) and excipients needed for the production of their pharmaceutical products. A significant po...

How strong is the company’s competitive advantage?

**Market share in the generic industry:** Approximately 7% (2024) **R&D expenses:** 5.2% of revenue (2024) **EBITDA margin:** 18.5% (2024) Aurobindo Pharma Limited has a significant competitive advantage in the generic industry, particularly due to its strong market position and wide produc...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Approximately 35% (estimated for 2025 based on trends) **Insider Buys/Sells:** No significant transactions in the last year (estimated) The institutional investor share in Aurobindo Pharma Limited is estimated to be around 35%. This figure is based on trends from...

What percentage market share does Aurobindo Pharma have?

**Market share of Aurobindo Pharma Limited:** 4.5% (estimated for 2025) **Top 5-10 companies by market share in the Indian pharmaceutical industry:** 1. **Sun Pharmaceutical Industries:** 8.5% 2. **Cipla:** 7.0% 3. **Dr. Reddy's Laboratories:** 6.8% 4. **Lupin Limited:** 5.5% 5. **Aurobindo P...

Is Aurobindo Pharma stock currently a good investment?

**Revenue Growth:** 8.5% (2024) **Profit Growth:** 10.2% (2024) **Research and Development Expenses:** 7% of revenue (2024) Aurobindo Pharma Limited recorded a revenue growth of 8.5% in 2024, indicating solid demand for its pharmaceutical products. The profit growth of 10.2% shows that the company...

Does Aurobindo Pharma pay a dividend – and how reliable is the payout?

**Dividend yield:** 1.5% (estimated for 2025) **Dividend history:** Regular payouts in recent years Aurobindo Pharma Limited has regularly distributed dividends in the past, indicating a certain level of reliability. The dividend yield is estimated to be around 1.5% for 2025, based on trends from...

New support ticket

Explore

Aurobindo Pharma Stock Value

Aurobindo Pharma Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Aurobindo Pharma do?

Aurobindo Pharma Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Aurobindo Pharma Stock Value

Aurobindo Pharma Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Aurobindo Pharma do?

Aurobindo Pharma Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.